Mayne Pharma Sues Sun Pharma Over IMVEXXY Patent Violations
In the lawsuit filed at the United States District Court for New Jersey, Mayne Pharma accused its rival of violating all 20 Orange Book-listed patents linked to IMVEXXY – a vaginal insert aimed at reducing pain during sexual intercourse after menopause.
Orange Book-listed patents are those approved by the U.S. Food and Drug Administration (FDA) and deemed safe to use.
The Australian drugmaker said it filed the lawsuit after a notification indicated Sun Pharma’s submission of an Abbreviated New Drug Application (ANDA) to the FDA seeking approval to market a generic version of IMVEXXY.
Manufacture the Medication in the United States
The ANDA is a request filed to the health regulator for approval of an already licensed drug to manufacture the medication in the United States. These application processes do not warrant the applicant to go through a clinical trial.
Sun Pharma did not immediately respond to a Reuters’ request for comment.
Mayne Pharma’s complaint also indicated that Sun Pharma filed a Paragraph IV certification, suggesting the latter challenged the patent’s (IMVEXXY) listing in the Orange Book as invalid or inapplicable.
This “formally initiates the litigation process under the Hatch-Waxman Act and triggers a 30-month stay of any potential FDA approval for Sun Pharma’s ANDA,” Mayne Pharma said in a statement.
IMVEXXY is distributed by TherapeuticsMD and had sealed the FDA’s approval in 2018.
Mutib Khalid is a skilled content writer and digital marketer with a knack for crafting compelling narratives and optimizing digital strategies. Excel in creating engaging content that drives results and enhances online presence. Passionate about blending creativity with data-driven approaches, Mutib Khalid helps brands connect with their audience and achieve their goals.
